The earlier women get the HPV vaccine, the better
UpdatedGrade ABig benefitLifespanHigh costLittle timeNo willpower
Data from 1.67 million Swedish women show that those who received the HPV vaccine before age 17 have only about one‑eighth the risk of developing invasive cervical cancer compared to unvaccinated women. For women vaccinated between 17 and 30, the risk is roughly half that of non‑vaccinated peers. Therefore, getting vaccinated earlier offers the greatest benefit.
- Cost
- Domestic bivalent vaccines cost around 300 RMB per dose, while imported 9‑valent vaccines cost about 1300 RMB per dose. A total of 2–3 doses are needed, and each visit takes half a day.
- Benefit
- Swedish research on 1.67 million women found that vaccinated individuals have a much lower incidence of invasive cervical cancer. Before age 17, vaccination reduces risk by roughly 88% (IRR 0.12, 95% CI 0.00–0.34). Vaccination between 17 and 30 still lowers risk by about 53% (IRR 0.47, 95% CI 0.27–0.75).
- Notes
- The greatest benefit is seen when vaccination occurs between ages 9 and 14. Even for women aged 17–30, risk is still reduced by more than half. After age 30, the protective effect gradually diminishes. Vaccinated women still need regular cervical cancer screening; the vaccine does not replace screening — see item 18 for screening guidelines for women over 30.
Sources · 1
- Lei J 等 (2020). HPV Vaccination and the Risk of Invasive Cervical Cancer. New England Journal of Medicine. doi.org/10.1056/NEJMoa1917338